Literature DB >> 8895161

Clinical significance of specific autoantibodies in juvenile dermatomyositis.

B M Feldman1, M Reichlin, R M Laxer, I N Targoff, L D Stein, E D Silverman.   

Abstract

OBJECTIVE: To determine the prevalence and clinical association of myositis specific antibodies in an unselected group of patients with juvenile dermatomyositis (DM).
METHODS: The sera of 42 subjects, representing an unselected group of patients from a single center, with juvenile DM and 7 others with idiopathic inflammatory myopathy (IIM) were examined for the presence of myositis specific antibodies by immunodiffusion against calf thymus extract and immunoprecipitation with HeLa extract.
RESULTS: Of the subjects with juvenile DM, only 2 had evidence of antibodies specific to myositis (anti-Mi2). Three other patients with juvenile DM had defined autoantibodies not usually considered to be specific to myositis. Two of the 3 subjects had anti-PM-Scl; both developed features of scleroderma after the juvenile DM remitted. The 5 subjects with defined autoantibodies did not differ clinically from the remainder of the subjects with the exception of the late development of scleroderma features in 2. Fourteen other subjects with juvenile DM had unidentified bands on immunoprecipitation, which may represent as yet undiscovered myositis specific antibodies. No myositis specific antibodies were detected in any of the 7 subjects with other IIM syndromes.
CONCLUSION: Based on our findings, we do not recommend routine clinical testing for these antibodies in children with typical juvenile DM. Further study of the unidentified bands seen in our subjects may lead to better understanding of the clinical groupings and etiopathogenesis of childhood myositis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8895161

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

Review 1.  Myositis-specific autoantibodies: detection and clinical associations.

Authors:  Sander H J van Dooren; Walther J van Venrooij; Ger J M Pruijn
Journal:  Auto Immun Highlights       Date:  2011-03-23

Review 2.  Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity.

Authors:  L M Pachman; T O Fedczyna; T S Lechman; J Lutz
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

Review 3.  [Connective tissue diseases in childhood].

Authors:  K Gensch; S Gudowius; T Niehues; A Kuhn
Journal:  Hautarzt       Date:  2005-10       Impact factor: 0.751

Review 4.  Juvenile dermatomyositis: advances in pathogenesis, evaluation, and treatment.

Authors:  Adam M Huber
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 5.  Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.

Authors:  Lucy R Wedderburn; Lisa G Rider
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-10       Impact factor: 4.098

6.  [Myositis-specific antibodies associated with juvenile dermatomyositis].

Authors:  K Eising; J Peitz; N Unterwalder; C Meisel; G Horneff
Journal:  Z Rheumatol       Date:  2018-10       Impact factor: 1.372

Review 7.  Novel autoantibodies and clinical phenotypes in adult and juvenile myositis.

Authors:  Zoe E Betteridge; Harsha Gunawardena; Neil J McHugh
Journal:  Arthritis Res Ther       Date:  2011-03-18       Impact factor: 5.156

8.  Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis.

Authors:  H Gunawardena; L R Wedderburn; H Chinoy; Z E Betteridge; J North; W E R Ollier; R G Cooper; C V Oddis; A V Ramanan; J E Davidson; N J McHugh
Journal:  Arthritis Rheum       Date:  2009-06

Review 9.  Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?

Authors:  Sarah L Tansley; Neil J McHugh; Lucy R Wedderburn
Journal:  Arthritis Res Ther       Date:  2013-04-08       Impact factor: 5.156

Review 10.  Clinical utility of antinuclear antibody tests in children.

Authors:  Julie L McGhee; Lauren M Kickingbird; James N Jarvis
Journal:  BMC Pediatr       Date:  2004-07-09       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.